本帖最后由 老马 于 2012-1-13 21:20 编辑
2 l7 U! d# B% R' m6 R E
0 C, j X5 g. C" ^) M8 j. O爱必妥和阿瓦斯丁的比较
! f' W9 l0 \. ?- w
1 o7 l; G: k5 t! ], J' Lhttp://cancergrace.org/lung/2008/08/30/bms099-os-neg/
0 ^: Y( ~$ S2 w0 |. {1 V1 T
2 _% ^9 p. O# b+ v* C! H9 \
, R5 w4 ~2 B4 q$ r) B
http://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/ l* r9 C( C0 v8 S0 t
==================================================
- q( i' E) s# S% T) U/ l. Q( G1 ~* e1 FOverall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
+ O/ W* Q& P; ], X" UPatients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
0 q1 B1 }! J# l2 f3 r/ W9 q1 N6 vResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (～62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
% X2 |# ]3 v& G* ]
|
显身卡
